Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021

Abstract

The COVID-19 vaccination programme commenced in England on 8 th December 2020 primarily based on age; by 7 th March 2021 approximately 93% of the English population aged 70+ years had received at least 1 dose of either the Pfizer BioNTech or AstraZeneca vaccines. Using a nucleoprotein assay that detects antibodies following natural infection only and a spike assay that detects infection and vaccine-induced responses, we aim to describe the impact of vaccination on SARS-CoV-2 antibody prevalence in English blood donors.

Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020

“…Our findings demonstrate both the feasibility and potential for broad application of using routinely collected blood samples to estimate community prevalence during a new outbreak. Now that a significant number of individuals have been vaccinated, it will be necessary to assay in parallel for antibodies to proteins in addition to spike ( 25 ).…”

Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the delta wave and vaccination

“…Recently, Whitaker et al ( 1 ) reported changes in SARS-CoV-2 seroprevalence in adults after introduction of a vaccination programme. Here we describe the impact of the delta wave and initiation of vaccination on seroprevalence in children.…”

Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom’s COVID-19 Public Health Response

“…Serology assay selection for different requirements is complex ( 28 ). This initial program was principally focused on serosurveillance; further work is now under way at UKHSA Porton to determine antibody responses induced by vaccination ( 29 ), vaccine effectiveness ( 30 ), vaccine coverage, variant infection, and population spread ( 31 ), using a combination of serology assays targeting different antigens. With additional assays now available, we have expanded our assays to encompass those with improved sensitivity and specificity, with the capability to change rapidly, enabling better and more accurate analysis of the differing and refined responses to the SARS-CoV-2.…”